Loading clinical trials...
Loading clinical trials...
To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
NCT05077904 · Stereotypical Prolonged Seizures
NCT06388707 · Drug Resistant Epilepsy, Epilepsy, and more
NCT07130786 · Seizures, Primary Motor Cortex, and more
NCT05667142 · Primary Generalized Tonic-Clonic Seizures
NCT07234695 · Down Syndrome, Down Syndrome (DS), and more
Pfizer Investigational Site
Bruges
Pfizer Investigational Site
Brussels
Pfizer Investigational Site
Duffel
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions